Skip to main content

Table 1 Baseline characteristics of tiotropium and placebo groups according to different threshold criteria for bronchodilator responsiveness.

From: Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial

  Criterion A (∆ % Predicted FEV1≥12% and ≥200 mL) Criterion B (∆ % Predicted FEV1≥15%) Criterion C (∆ % Predicted FEV1≥10%)
  Nonresponder (n = 2750) Responder (n = 3033) Nonresponder (n = 1995) Responder (n = 3788) Nonresponder (n = 3553) Responder (n = 2230)
  Tio (n = 1357) Placebo (n = 1393) Tio (n = 1520) Placebo (n = 1513) Tio (n = 995) Placebo (n = 1000) Tio (n = 1882) Placebo (n = 1906) Tio (n = 1769) Placebo (n = 1784) Tio (n = 1108) Placebo(n = 1122)
Age (years) 64.9 ± 8.4 65.3 ± 8.4 64.1 ± 8.4 63.8 ± 8.5 64.4 ± 8.3 64.5 ± 8.5 64.5 ± 8.5 64.5 ± 8.5 64.4 ± 8.3 64.6 ± 8.4 64.7 ± 8.6 64.3 ± 8.7
Male, % 69.7 69.2 80.2 78.6 77.0 75.7 74.3 73.2 76.2 75.6 73.7 71.7
Smoking history (%)             
   Ex-smoker 69.6 70.7 71.6 69.3 67.8 67.5 72.1 71.2 69.3 70.7 72.727.3 68.8
   Current smoker 30.4 29.3 28.4 30.7 32.2 32.5 27.9 28.8 30.7 29.3   31.2
Mean COPD duration (years) 10.1 ± 7.7 9.8 ± 7.7 9.7 ± 7.5 9.6 ± 7.0 9.9 ± 7.6 9.7 ± 7.5 9.9 ± 7.5 9.7 ± 7.3 10.1 ± 7.7 9.7 ± 7.5 9.6 ± 7.4 9.6 ± 7.1
Baseline medication* use (%)             
   LABA 60.0 61.5 59.7 59.1 56.9 59.1 61.4 60.8 59.8 61.7 59.9 57.8
   ICS 62.1 62.5 60.8 60.7 58.9 59.9 62.8 62.4 61.6 61.7 61.2 61.4
   Combination ICS+LABA 49.2 50.0 48.4 47.3 45.2 47.6 50.6 49.1 48.5 49.7 49.1 46.7
   Anticholinergic 46.9 47.6 44.9 42.7 44.0 43.9 46.8 45.6 47.1 45.8 43.9 43.9
   Theophyllines 31.6 33.0 26.3 24.3 29.0 31.4 28.7 27.0 30.7 31.7 25.8 23.4
SGRQ total score (units) 47.2 ± 17.2 48.0 ± 17.5 44.5 ± 16.7 43.9 ± 16.7 45.4 ± 17.5 46.6 ± 17.8 46.0 ± 16.7 45.5 ± 16.9 46.9 ± 17.2 47.1 ± 17.2 44.0 ± 16.6 43.9 ± 17.0
  1. Data expressed as either proportions or mean ± SD.
  2. Tio = tiotropium; LABA = long-acting β-acting agonist; ICS = inhaled corticosteroid; SGRQ = St. George's Respiratory Questionnaire; GOLD = Global Initiative for Chronic Obstructive Lung Disease.
  3. *baseline maintenance inhaled respiratory medication.
\